All In Biotech

Free tool

FAERS Monitor: Pombiliti

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761204 or its brand name (Pombiliti, Cipaglucosidase Alfa-Atga). Reports on generic versions are filed under their own applications.

Reports

91

Serious

47

52% of reports

Hospitalization

19

Death reported

9

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue10
  • nausea10
  • asthenia7
  • product dose omission issue7
  • vomiting7
  • malaise6
  • death5
  • dyspnoea5
  • headache5
  • hypertension5
  • infusion related reaction5
  • pneumonia5
  • abdominal discomfort4
  • abdominal pain upper4
  • dizziness4

Reports by year received

View as table
YearReports
202428
202530
202633

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,068 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infusion related reactionSignal517.47.462
abdominal discomfortSignal45.52.111
product dose omission issueSignal75.52.722
hypertensionSignal55.52.314
abdominal pain upperSignal44.51.78
astheniaSignal74.32.115
pneumoniaSignal53.61.57
vomitingSignal73.41.710
malaiseSignal63.21.57
fatigueSignal103.01.712
nauseaSignal102.91.611
dyspnoea52.00.92
dizziness41.90.71
headache51.80.81
death51.30.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.